Pear Therapeutics, Inc. (NASDAQ:PEAR) Insider Ronan O’brien Sells 12,162 Shares

Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) insider Ronan O’brien sold 12,162 shares of the firm’s stock in a transaction dated Friday, January 20th. The shares were sold at an average price of $1.13, for a total transaction of $13,743.06. Following the completion of the sale, the insider now owns 18,638 shares of the company’s stock, valued at approximately $21,060.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pear Therapeutics Stock Performance

Shares of NASDAQ:PEAR traded down $0.01 during midday trading on Tuesday, hitting $1.12. 187,569 shares of the company’s stock traded hands, compared to its average volume of 233,738. The company has a market cap of $156.83 million, a PE ratio of -5.09 and a beta of 0.87. The firm’s fifty day moving average price is $1.53 and its two-hundred day moving average price is $1.82. Pear Therapeutics, Inc. has a twelve month low of $0.98 and a twelve month high of $6.74.

Pear Therapeutics (NASDAQ:PEAR – Get Rating) last posted its earnings results on Monday, November 14th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.01). The business had revenue of $4.08 million for the quarter. Pear Therapeutics had a negative net margin of 265.26% and a negative return on equity of 185.33%. As a group, equities research analysts anticipate that Pear Therapeutics, Inc. will post -0.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Pear Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its stake in Pear Therapeutics by 1,310.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 167,851 shares of the company’s stock worth $342,000 after buying an additional 155,952 shares during the period. California State Teachers Retirement System purchased a new stake in Pear Therapeutics during the 3rd quarter worth $55,000. BNP Paribas Arbitrage SNC purchased a new stake in Pear Therapeutics during the 3rd quarter worth $50,000. State Street Corp increased its stake in Pear Therapeutics by 195.8% during the 3rd quarter. State Street Corp now owns 923,012 shares of the company’s stock worth $1,883,000 after buying an additional 610,984 shares during the period. Finally, Verdence Capital Advisors LLC purchased a new stake in Pear Therapeutics during the 3rd quarter worth $28,000. Institutional investors and hedge funds own 71.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Chardan Capital dropped their target price on shares of Pear Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, November 15th. Credit Suisse Group lowered their target price on shares of Pear Therapeutics from $9.00 to $7.00 and set an “outperform” rating for the company in a research note on Tuesday, November 15th. Finally, Citigroup decreased their price target on shares of Pear Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, November 16th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Pear Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $6.25.

Pear Therapeutics Company Profile

(Get Rating)

Pear Therapeutics, Inc, a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia.